RecruitingPhase I/IIEN originalLymphomaLeukemiaOther cancers

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body, which may help to control the disease.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Rozpoznanie białaczki, chłoniaka lub szpiczaka mnożakowego, u którego nowotwór wykazuje określony marker (CD70) w co najmniej 10%
  • Przerwa co najmniej 1 tygodnia od ostatniej chemioterapii przed rozpoczęciem leczenia przygotowującego
  • Dobra funkcja nerek, wątroby, serca i płuc potwierdzona badaniami
  • Wiek od 12 do 80 lat
  • Waga co najmniej 40 kg
  • Stan ogólny pacjenta pozwalający na podjęcie leczenia
  • Zdolność do udzielenia świadomej zgody na udział w badaniu
  • Stosowanie skutecznej antykoncepcji przez osoby zdolne do posiadania dzieci podczas badania i przez 3 miesiące po

Simplified criteria — AI translation

Trial details

Minimum age
12 Years
Maximum age
80 Years
Last updated (source)
August 7, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (1)

M D Anderson Cancer Center

Houston, United States

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/8/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.